Healthcare
Synovics Pharmaceuticals, Inc.(SYVC)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- +10.6%
- EPS Growth
- +84.4%
- Dividend Yield
- 0.0%
Coverage: 251 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synovics Pharmaceuticals, Inc. (SYVC) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +84.4%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +84.4%, free cash flow +171.8% with operating margin -9.6% and ROIC -21.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines SYVC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.6% vs +7.6% peer median
Operating Margin
Below sector median
-9.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +10.6% and EPS at +84.4%, with operating margin around -9.6%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYVC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYVC Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYVC and SPY.
Company Overview
Synovics Pharmaceuticals, Inc.
Other OTC
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
- Leadership
- John R. Palmer
- IPO Date
- Jun 26, 2023
- Employees
- 155
- Street Address
- 5360 Northwest 35th Avenue
- Mailing
- Fort Lauderdale
- Region
- Fort Lauderdale, US
- Reporting Currency
- USD
- Investor Line
- +1 415 659 0590
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +10.6%
- EPS
- +84.4%
- Free Cash Flow
- +171.8%
Profitability
- Gross Margin
- 34.6%
- Operating Margin
- -9.6%
- Net Margin
- -15.4%
- ROE
- 258.2%
- ROIC
- -21.5%
Balance Sheet
- Debt/Equity
- 1.31
- Current Ratio
- 0.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.